Primary information |
---|
sequence ID | Seq_934 |
Peptide sequence | AVHKAVLTIDEKGTEAAGAM |
CancerPDF_ID | CancerPDF_ID9510, CancerPDF_ID9511, |
PMID | 21533267,21533267 |
Protein Name | Alpha-1-antitrypsin,Alpha-1-antitrypsin |
UniprotKB Entry Name | A1AT_HUMAN,A1AT_HUMAN |
Fluid | Serum,Serum |
M/Z | 671.35,676.68 |
Charge | 3,3 |
Mass (in Da) | NA,NA |
fdr | NA,NA |
Profiling Technique | LC-MS,LC-MS |
Peptide Identification technique | LC/MS/MS,LC/MS/MS |
Quantification Technique | Multiple Reaction Monitoring,Multiple Reaction Monitoring |
Labelled/Label Free | Label Free,Label Free |
FDR | 1.49,1.49 |
CancerPDF_ID | CancerPDF_ID9510, CancerPDF_ID9511, |
p-Value | NA,NA |
Software | MASCOT,MASCOT |
Length | 20,20 |
Cancer Type | Lung adenocarcinoma,Lung adenocarcinoma |
Database | Swissprot Database (57.4),Swissprot Database (57.4) |
Modification | NA,Oxidation |
Number of Patients | 62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
Validation | MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
Sensitivity | NA,NA |
Specificity | NA,NA |
Accuracy | NA,NA |
Peptide Atlas | NA |
IEDB | |